Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are pleased to announce that Professor Freddie Hamdy’s PART trial has been funded by the NIHR HTA. PART is a feasibility, randomised controlled trial which will compare partial ablation (PA) with radical prostatectomy (RP) in men with intermediate risk unilateral prostate cancer.

Situ has a new trial

As the PART study is a feasibility study, embedded within it is a qualitative research investigation (QRI), which will be led by a team at the University of Bristol. This will include interviews with the research team and patients in order to understand the issues surrounding recruitment. It is intended that the results from this will later inform a recruitment strategy for a full trial.

Recruitment is scheduled to start at the beginning of 2015, and the team is currently working on developing trial documentation and submitting for ethical approval.
We are also excited to welcome a new team member, the PART Trial Manager, who will be joining us to work on the PART trial.